Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.
A company called Curis is testing a medicine that might help people with blood cancer, and early results look promising. When a medicine shows promise, people get more interested in the company, so it's worth watching what happens when they release their full December results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.